Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile

A 2-year study evaluation

Giuseppe Derosa, Pietro Dario Ragonesi, Elena Fogari, Arrigo Francesco Giuseppe Cicero, Lucio Bianchi, Aldo Bonaventura, Davide Romano, Pamela Maffioli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The aim of this study was to evaluate whether the positive effects of sitagliptin on glycemic control and insulin resistance were maintained also after 2 years of therapy and whether sitagliptin could be effective also in improving lipid profile. In this randomized, double-blind, placebo-controlled trial, 205 patients with type 2 diabetes in therapy with different antidiabetic drugs were randomized to add sitagliptin 100 mg once a day or placebo to their current therapy. We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg). Sitagliptin, added to previously taken antidiabetic agents, proved to be effective in improving glycemic profile, reducing HbA1c by -17.5%, FPG by -12.7%, PPG by -20.5%. Regarding insulin resistance, sitagliptin decreased FPI by -8.3% and HOMA-IR by -20.0%, confirming that what have been already reported in short-term studies can be applied also after 2 years of treatment. Sitagliptin also reduced body weight by -4.3%. Our study also showed the positive effect of sitagliptin on lipid profile; in particular, sitagliptin decreased TC by -13.3%, LDL-C by -20.4%, and Tg by -32.3%, and also increased HDL-C by + 13.6%. Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalFundamental and Clinical Pharmacology
Volume28
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

varespladib methyl
Hypoglycemic Agents
Insulin Resistance
Lipids
Fasting
Glucose
LDL Cholesterol
HDL Cholesterol
Homeostasis
Cholesterol
Placebos
Body Weight
Insulin
Therapeutics
Sitagliptin Phosphate
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Body Mass Index

Keywords

  • DPP-4 inhibitors
  • Glycemic control
  • Insulin resistance
  • Lipid profile
  • Sitagliptin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile : A 2-year study evaluation. / Derosa, Giuseppe; Ragonesi, Pietro Dario; Fogari, Elena; Cicero, Arrigo Francesco Giuseppe; Bianchi, Lucio; Bonaventura, Aldo; Romano, Davide; Maffioli, Pamela.

In: Fundamental and Clinical Pharmacology, Vol. 28, No. 2, 2014, p. 221-229.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Ragonesi, Pietro Dario ; Fogari, Elena ; Cicero, Arrigo Francesco Giuseppe ; Bianchi, Lucio ; Bonaventura, Aldo ; Romano, Davide ; Maffioli, Pamela. / Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile : A 2-year study evaluation. In: Fundamental and Clinical Pharmacology. 2014 ; Vol. 28, No. 2. pp. 221-229.
@article{d3b1c74f6aa94b1baaa296027de91c7a,
title = "Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: A 2-year study evaluation",
abstract = "The aim of this study was to evaluate whether the positive effects of sitagliptin on glycemic control and insulin resistance were maintained also after 2 years of therapy and whether sitagliptin could be effective also in improving lipid profile. In this randomized, double-blind, placebo-controlled trial, 205 patients with type 2 diabetes in therapy with different antidiabetic drugs were randomized to add sitagliptin 100 mg once a day or placebo to their current therapy. We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg). Sitagliptin, added to previously taken antidiabetic agents, proved to be effective in improving glycemic profile, reducing HbA1c by -17.5{\%}, FPG by -12.7{\%}, PPG by -20.5{\%}. Regarding insulin resistance, sitagliptin decreased FPI by -8.3{\%} and HOMA-IR by -20.0{\%}, confirming that what have been already reported in short-term studies can be applied also after 2 years of treatment. Sitagliptin also reduced body weight by -4.3{\%}. Our study also showed the positive effect of sitagliptin on lipid profile; in particular, sitagliptin decreased TC by -13.3{\%}, LDL-C by -20.4{\%}, and Tg by -32.3{\%}, and also increased HDL-C by + 13.6{\%}. Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile.",
keywords = "DPP-4 inhibitors, Glycemic control, Insulin resistance, Lipid profile, Sitagliptin",
author = "Giuseppe Derosa and Ragonesi, {Pietro Dario} and Elena Fogari and Cicero, {Arrigo Francesco Giuseppe} and Lucio Bianchi and Aldo Bonaventura and Davide Romano and Pamela Maffioli",
year = "2014",
doi = "10.1111/fcp.12001",
language = "English",
volume = "28",
pages = "221--229",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile

T2 - A 2-year study evaluation

AU - Derosa, Giuseppe

AU - Ragonesi, Pietro Dario

AU - Fogari, Elena

AU - Cicero, Arrigo Francesco Giuseppe

AU - Bianchi, Lucio

AU - Bonaventura, Aldo

AU - Romano, Davide

AU - Maffioli, Pamela

PY - 2014

Y1 - 2014

N2 - The aim of this study was to evaluate whether the positive effects of sitagliptin on glycemic control and insulin resistance were maintained also after 2 years of therapy and whether sitagliptin could be effective also in improving lipid profile. In this randomized, double-blind, placebo-controlled trial, 205 patients with type 2 diabetes in therapy with different antidiabetic drugs were randomized to add sitagliptin 100 mg once a day or placebo to their current therapy. We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg). Sitagliptin, added to previously taken antidiabetic agents, proved to be effective in improving glycemic profile, reducing HbA1c by -17.5%, FPG by -12.7%, PPG by -20.5%. Regarding insulin resistance, sitagliptin decreased FPI by -8.3% and HOMA-IR by -20.0%, confirming that what have been already reported in short-term studies can be applied also after 2 years of treatment. Sitagliptin also reduced body weight by -4.3%. Our study also showed the positive effect of sitagliptin on lipid profile; in particular, sitagliptin decreased TC by -13.3%, LDL-C by -20.4%, and Tg by -32.3%, and also increased HDL-C by + 13.6%. Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile.

AB - The aim of this study was to evaluate whether the positive effects of sitagliptin on glycemic control and insulin resistance were maintained also after 2 years of therapy and whether sitagliptin could be effective also in improving lipid profile. In this randomized, double-blind, placebo-controlled trial, 205 patients with type 2 diabetes in therapy with different antidiabetic drugs were randomized to add sitagliptin 100 mg once a day or placebo to their current therapy. We evaluated at the baseline and after 6, 12, 18, and 24 months the following parameters: body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg). Sitagliptin, added to previously taken antidiabetic agents, proved to be effective in improving glycemic profile, reducing HbA1c by -17.5%, FPG by -12.7%, PPG by -20.5%. Regarding insulin resistance, sitagliptin decreased FPI by -8.3% and HOMA-IR by -20.0%, confirming that what have been already reported in short-term studies can be applied also after 2 years of treatment. Sitagliptin also reduced body weight by -4.3%. Our study also showed the positive effect of sitagliptin on lipid profile; in particular, sitagliptin decreased TC by -13.3%, LDL-C by -20.4%, and Tg by -32.3%, and also increased HDL-C by + 13.6%. Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile.

KW - DPP-4 inhibitors

KW - Glycemic control

KW - Insulin resistance

KW - Lipid profile

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84895529499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895529499&partnerID=8YFLogxK

U2 - 10.1111/fcp.12001

DO - 10.1111/fcp.12001

M3 - Article

VL - 28

SP - 221

EP - 229

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 2

ER -